Organicin Scientific

Organicin Scientific is a Boston-based biotechnology company working on bacteriocins — antimicrobial proteins produced by bacteria that selectively target competing bacteria. The company's stated approach is to discover and characterize naturally occurring bacteriocins rather than design new antimicrobials from scratch, and to advance candidates toward applications in animal health, nutrition, and microbiome products. Its positioning centers on antimicrobial resistance (AMR) in both agriculture and human health, with early programs directed at pathogens listed among the CDC's "Biggest Threats" in its 2019 antibiotic resistance report.

The company's core asset is CinThesis, a computational discovery platform and research workspace that combines six analytical perspectives on candidate molecules: molecular/physicochemical properties, secondary structure, predicted 3D structure, domain architecture, sequence embeddings, and evolutionary context. CinThesis is paired with an indexed research catalogue spanning literature, protein sequences, gene records, genomes, and antimicrobial activity measurements such as MIC values and inhibition zones. The company reports bacteriocin prediction performance of 98.68% accuracy across 4,482 evaluated sequences, compared with 93.95% for a machine-learning-only baseline. Platform access is offered for discovery programs and academic research, alongside collaboration arrangements built around a specific target or application.

Product work to date has included a bacteriocin-based shrimp feed additive targeting acute hepatopancreatic necrosis disease (AHPND), a condition the company has described as causing roughly $7 billion in annual losses to the shrimp industry. Earlier work described drug candidates formulated into biopesticides for plant diseases affecting farms and orchards, including fire blight. A stated pipeline direction covers necrotic enteritis in poultry, swine-industry challenges, and preliminary work in human health indications such as acne and H. pylori-related conditions.

Founding story

The company originated in undergraduate research at the University of Massachusetts Amherst. Co-founder Mathew Mitchell has described a family experience with antibiotic-resistant superinfections as the motivation for pursuing antimicrobial work, and subsequently joined the laboratory of Dr. Margaret Riley, which studied bacteriocins as a means of combating antibiotic resistance. Mitchell incorporated Organicin out of that undergraduate work and co-founded the company with lab colleagues to commercialize bacteriocins, continuing through his graduate and medical studies.

Business model

Organicin develops bacteriocin candidates through its CinThesis discovery platform and makes platform access available for discovery programs and academic research, alongside collaborations structured around a specific target, application, or scientific question.

The company has described a strategy of licensing its intellectual property to established industry players that hold sales and distribution networks, with those commercialization partners also supporting product development and regulatory strategy.

Traction

Reported validation includes two trials of the bacteriocin-based shrimp feed additive showing statistically significant improvements in shrimp survival, with increases of up to 165%. The company has stated it found successes in treating pathogens listed among the CDC's "Biggest Threats," and reports collaborations with shrimp feed companies. Recognition includes the 2023 XTC/UN World Food Forum Startup Innovation Award (Better Environment) and participation in Techstars Farm to Fork 2022. The CinThesis catalogue, as of September 5, 2026, indexes 359k+ research articles, 59k+ protein sequences, 1.8M+ gene records, 529 genomes, and 18k+ antimicrobial activity records.

Latest developments

Company materials describe the CinThesis research workspace, including a walkthrough of the platform, benchmark prediction metrics, and an indexed research catalogue current as of September 5, 2026, with access offered for discovery programs and academic research.